Lockdown and dementia: For some, COVID-19 has created an isolated, confusing but calmer world

by Catherine Talbot,The ConversationCredit: AI-generated imageThe approximately850,000people living with dementia in the UK have been badly affected by COVID-19. Many live in care ho

Updated on: June 01,2024

Lockdown and dementia: For some, COVID-19 has created an isolated, confusing but calmer world

by Catherine Talbot,The ConversationCredit: AI-generated imageThe approximately850,000people living with dementia in the UK have been badly affected by COVID-19. Many live in care ho

Updated on:June 01,2024

Experiments on mice reveal the parts of the brain involved in motion sickness

by Bob Yirka , Medical XpressIdentification of glutamatergic neuronal subpopulations in the VN. (A)Slc17a6Cremice were bilaterally injected in the VN with a viral vector expressing the Rib

Updated on: January 11,2024

Experiments on mice reveal the parts of the brain involved in motion sickness

by Bob Yirka , Medical XpressIdentification of glutamatergic neuronal subpopulations in the VN. (A)Slc17a6Cremice were bilaterally injected in the VN with a viral vector expressing the Rib

Updated on:January 11,2024

Cooperation advances Alzheimer's disease prevention research

by GYMRThe future success of Alzheimer's prevention research could depend on the ability of researchers from different clinical trials to build collaborative relationships that facilitate the shar

Updated on: February 26,2024

Cooperation advances Alzheimer's disease prevention research

by GYMRThe future success of Alzheimer's prevention research could depend on the ability of researchers from different clinical trials to build collaborative relationships that facilitate the shar

Updated on:February 26,2024

A new mechanism for crossing the blood–brain barrier

by Lori Dajose,California Institute of TechnologyCA-IV is required for the CNS potency of Car4-dependent AAV. (A) Immunostaining for CA-IV in the brains of WT/WT and KO/KO Car4 mice. Magnified r

Updated on: February 05,2024

A new mechanism for crossing the blood–brain barrier

by Lori Dajose,California Institute of TechnologyCA-IV is required for the CNS potency of Car4-dependent AAV. (A) Immunostaining for CA-IV in the brains of WT/WT and KO/KO Car4 mice. Magnified r

Updated on:February 05,2024

Carriers of Alzheimer's genetic marker have greater difficulty harnessing past knowledge

by Baycrest Centre for Geriatric CareDr. Claude Alain, a senior author on the paper and senior scientist at Baycrest's Rotman Research Institute. Credit: Provided by Baycrest.Adults carrying

Updated on: April 23,2024

Carriers of Alzheimer's genetic marker have greater difficulty harnessing past knowledge

by Baycrest Centre for Geriatric CareDr. Claude Alain, a senior author on the paper and senior scientist at Baycrest's Rotman Research Institute. Credit: Provided by Baycrest.Adults carrying

Updated on:April 23,2024

Neural prosthetic device can help humans restore memory

byAtrium Health Wake Forest BaptistDelayed match to sample (DMS) task performed on a touch screen by patients seated in either the hospital bed or a chair. Trial is started by patient touching a

Updated on: March 13,2024

Neural prosthetic device can help humans restore memory

byAtrium Health Wake Forest BaptistDelayed match to sample (DMS) task performed on a touch screen by patients seated in either the hospital bed or a chair. Trial is started by patient touching a

Updated on:March 13,2024

Is a commonly-used screening tool for cognitive impairment accurate in diverse populations?

by WileyCredit: Pixabay/CC0 Public DomainA screening tool often used in primary care clinics to detect cognitive impairment has shortcomings when applied to ethnically and linguistically diverse

Updated on: February 24,2024

Is a commonly-used screening tool for cognitive impairment accurate in diverse populations?

by WileyCredit: Pixabay/CC0 Public DomainA screening tool often used in primary care clinics to detect cognitive impairment has shortcomings when applied to ethnically and linguistically diverse

Updated on:February 24,2024

Touchscreens and milkshakes: Study reveals more about brain's reward systems

by Cam Buchan,University of Western OntarioThe touchscreen Autoshaping task to assess Pavlovian approach behaviors toward reward-predicting stimuli. a Layout of the Autoshaping touchscreen opera

Updated on: February 03,2024

Touchscreens and milkshakes: Study reveals more about brain's reward systems

by Cam Buchan,University of Western OntarioThe touchscreen Autoshaping task to assess Pavlovian approach behaviors toward reward-predicting stimuli. a Layout of the Autoshaping touchscreen opera

Updated on:February 03,2024

Study opens the door to earlier diagnosis and potential treatment for Alzheimer's disease

by Aarhus UniversityLarge Aβ Agg [+] MCI patients display lower AD-like brain pathology than large Aβ Agg [-] MCI.a18F-FTP PET uptake in each group at baseline, two-year follow-up, an

Updated on: March 19,2024

Study opens the door to earlier diagnosis and potential treatment for Alzheimer's disease

by Aarhus UniversityLarge Aβ Agg [+] MCI patients display lower AD-like brain pathology than large Aβ Agg [-] MCI.a18F-FTP PET uptake in each group at baseline, two-year follow-up, an

Updated on:March 19,2024

Physicists overturn common assumptions regarding brain activity

byBar-Ilan UniversityCredit: Pixabay/CC0 Public DomainThe brain is a complex network containing billions of neurons. The soma of each of these neurons communicates simultaneously with thousands

Updated on: January 10,2024

Physicists overturn common assumptions regarding brain activity

byBar-Ilan UniversityCredit: Pixabay/CC0 Public DomainThe brain is a complex network containing billions of neurons. The soma of each of these neurons communicates simultaneously with thousands

Updated on:January 10,2024

FDA approves Vyalev for advanced Parkinson's disease

by Lori SolomonThe U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson's disease (PD).Vyalev is the first an

Updated on: November 07,2024

FDA approves Vyalev for advanced Parkinson's disease

by Lori SolomonThe U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson's disease (PD).Vyalev is the first an

Updated on:November 07,2024

Senescent glial cell: A key player in lipid accumulation and brain aging

Updated on: October 21,2024

Senescent glial cell: A key player in lipid accumulation and brain aging

Updated on:October 21,2024